Foamix to Present Corporate Overview at the 28th Annual ROTH Conference

REHOVOT, Israel and BRIDGEWATER, N.J., March 07, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, Chief Executive Officer, will provide a corporate overview and business update at the 28th Annual ROTH Conference, taking place in Orange County, California, March 13-16, 2016.

Presentation Details:
Title:28th Annual ROTH Conference
Date:Monday, March 14
Time:4:30pm Pacific Time
Location:Ritz Carlton, Orange County, California

About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX 103 for the treatment of rosacea, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium. For more information, please visit

Contact: Dorit Hayon, BD Foamix Pharmaceuticals Ltd. +972-8-9316233 US Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979

Source:Foamix, Ltd.